Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Intratracheal Inbubation
Interventions: Intubation with GlideScope, Intubation with Airway Scope; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab, Placebo; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more

Conditions: Post Surgical Neuropathic Pain
Interventions: Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system; Drug
Lead sponsor: Averitas Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 23
States / cities: Tucson, Arizona • Vista, California • Washington D.C., District of Columbia + 19 more

Conditions: Generalized Anxiety Disorder
Interventions: Applied relaxation and self-control desensitization, Cognitive therapy (CT), Cognitive-Behavioral Therapy; Behavioral · Other
Lead sponsor: Michelle G. Newman; Other
Eligibility: 18 Years to 85 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 1998
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Liver Transplant Rejection
Interventions: CFZ533, Tacrolimus - MMF - corticosteroids; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Anesthesia
Interventions: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%, Tetracaine HCl 3%, Placebo; Drug
Lead sponsor: St. Renatus, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Buffalo, New York • Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: Placebo, Metformin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Skin Disorder
Interventions: Diffuse Reflectance Spectroscopy, BiliChek; Device · Diagnostic Test
Lead sponsor: University of Arkansas; Other
Eligibility: 24 Hours to 6 Months
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Type 2 Diabetes, T2D
Interventions: Insulin Efsitora Alfa, Insulin Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 39
States / cities: Birmingham, Alabama • Sheffield, Alabama • Escondido, California + 35 more

Conditions: Maternal Depression, Parenting Behavior, Health, Interpersonal Relationships, Goal Directed Behavior, Child Behavior, Child School Readiness
Interventions: Interpersonal Psychotherapy for Depression -Group; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: Female only
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions: MarzAA; Biological
Lead sponsor: Catalyst Biosciences; Industry
Eligibility: 12 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia

Conditions: Chronic Kidney Disease
Interventions: Sodium bicarbonate, Controlled diet; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 22 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acne Vulgaris
Interventions: Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan); Drug · Other
Lead sponsor: Seegpharm S.A.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 2,361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 35
States / cities: Encino, California • Fullerton, California • La Mesa, California + 29 more

Conditions: Dental Plaque
Interventions: Fluoride, Triclosan/Fluoride; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years to 53 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Survivors of Childhood Cancer, Substance Use
Interventions: WHO ASSIST v3.1 Screening with Feedback, ASSIST Linked Brief Intervention (10 Step Motivational interviewing (MI)/FRAMES), WHO ASSIST v3.1 Screening (No Feedback); Behavioral
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 15 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Acne Vulgaris
Interventions: Sarecycline, Placebo; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 9 Years to 45 Years
Enrollment: 1,034 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 57
States / cities: Mobile, Alabama • Hot Springs, Arkansas • Carlsbad, California + 52 more

Conditions: Moderate Hepatic Impairment
Interventions: Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Tustin, California • Miami, Florida • Orlando, Florida

Conditions: Healthy
Interventions: Hylenex; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489; Drug
Lead sponsor: Shire; Industry
Eligibility: 4 Years to 5 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 48
States / cities: Dothan, Alabama • Little Rock, Arkansas • Colton, California + 39 more

Conditions: Huntington Disease
Interventions: Tominersen, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years to 50 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 15 more

Conditions: Inflammation, Pain, Cataract
Interventions: XG-102, Placebo; Drug
Lead sponsor: Xigen SA; Industry
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Obesity
Interventions: FB Professional LED Red light therapy, Effects of Red Light LED Therapy on Body Contouring; Device
Lead sponsor: Manamed Inc.; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: Alzheimer Disease
Interventions: DMXB-A; Drug
Lead sponsor: CoMentis; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: 280 South San Francisco, California

Search by objective public record fields.

Airway Scope vs GlideScope for Intubation in Obese Patients

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome

Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults

Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer

Characterization of Pre-Term Neonatal Skin

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

Healthy Moms-Healthy Kids: Reducing Maternal Depression for Better Outcomes in Head Start Children

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Acid-Base Compensation in Chronic Kidney Disease

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

Clinical Study to Compare Dental Plaque Control

Feasibility of Incorporating a Standardized Substance Use Measure With Linked-Brief Intervention Into Routine Psychosocial Care of Adult Childhood Cancer Survivors

Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

Effects of Red Light LED Therapy on Body Contouring

GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease